Ticker | ZBH | Earnings Date | August 5, 2026 (8:30 AM ET) |
Reporting Period | Q2 2026 (quarter ended June 30, 2026) | Prepared | August 4, 2026 |
Last Earnings | April 28, 2026 (Q1 2026) | Sector ETF Benchmark | iShares U.S. Medical Devices ETF (IHI) |
Quarter | KPI | Reported | Consensus | Surprise % | Result |
Q1 2026 | Total Revenue | $2,086.7M | $2,069.0M | +0.9% | Beat |
Q1 2026 | Adj. EPS | $2.09 | $1.86 | +12.4% | Beat |
Q4 2025 | Total Revenue | $2,243.8M | $2,224.3M | +0.9% | Beat |
Q4 2025 | Adj. EPS | $2.42 | $2.39 | +1.3% | Beat |
Q3 2025 | Total Revenue | $2,001.4M | $2,010.7M | -0.5% | Miss |
Q3 2025 | Adj. EPS | $1.90 | $1.88 | +1.1% | Beat |
Q2 2025 | Total Revenue | $2,077.3M | $2,046.0M | +1.5% | Beat |
Q2 2025 | Adj. EPS | $2.07 | $1.97 | +5.1% | Beat |
Q1 2025 | Total Revenue | $1,909.1M | $1,895.0M | +0.7% | Beat |
Q1 2025 | Adj. EPS | $1.81 | $1.76 | +2.8% | Beat |
Q4 2024 | Total Revenue | $2,023.2M | $2,014.7M | +0.4% | Beat |
Q4 2024 | Adj. EPS | $2.31 | $2.30 | +0.4% | Beat |
Q3 2024 | Total Revenue | $1,824.2M | $1,797.8M | +1.5% | Beat |
Q3 2024 | Adj. EPS | $1.74 | $1.74 | 0.0% | In-Line |
Pattern: ZBH has beaten revenue consensus in 7 of the last 8 quarters, with the sole miss in Q3 2025 (a known weak quarter). EPS beats have been consistent but the magnitude varies significantly — the Q1 2026 beat was outsized due to the non-recurring tariff benefit. Expect a more modest EPS beat or in-line result in Q2 absent another one-time item.
Source: Visible Alpha consensus and actuals data.